Horizon Pharma to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

Horizon Pharma to Present at the 21st Annual Future Leaders in the Biotech 
Industry Conference 
DEERFIELD, IL -- (Marketwired) -- 03/25/14 --  Horizon Pharma, Inc.
(NASDAQ: HZNP) today announced that Timothy P. Walbert, its chairman,
president and chief executive officer, will present at the 21st
Annual Future Leaders in the Biotech Industry Conference on Friday,
March 28, 2014 at 3:30 p.m. Eastern Time in New York, NY. Mr. Walbert
will provide an overview of Horizon and its corporate activities. 
The presentation will be webcast live and may be accessed by visiting
Horizon's website at 
 http://ir.horizon-pharma.com. A replay of the
webcast will be available on Horizon's website for 10 business days.  
About Horizon Pharma
 Horizon Pharma, Inc. is a commercial stage,
specialty pharmaceutical company that markets DUEXIS(R), VIMOVO(R)
and RAYOS(R)/LODOTRA(R), which target unmet therapeutic needs in
arthritis, pain and inflammatory diseases. The Company's strategy is
to develop, acquire or in-license additional innovative medicines
where it can execute a targeted commercial approach among specific
target physicians such as primary care physicians, orthopedic
surgeons and rheumatologists, while taking advantage of its
commercial strengths and the infrastructure the Company has put in
place. For more information, please visit www.horizonpharma.com. 
Additional Information and Where to Find It  
In connection with a proposed transaction with Vidara Therapeutics
International Ltd., Horizon and Vidara will be filing documents with
the SEC, including the filing by Horizon of a preliminary and
definitive proxy statement/prospectus relating to the proposed
transaction and the filing by Vidara of a registration statement on
Form S-4 that will include the proxy statement/prospectus relating to
the proposed transaction. After the registration statement has been
declared effective by the SEC, a definitive proxy
statement/prospectus will be mailed to Horizon stockholders in
connection with the proposed transaction. INVESTORS AND SECURITY
HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT ON FORM S-4 AND
THE RELATED PRELIMINARY AND DEFINITIVE PROXY/PROSPECTUS WHEN THEY
BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT HORIZON, VIDARA AND THE PROPOSED TRANSACTION. Investors and
security holders may obtain free copies of these documents (when they
are available) and other related documents filed with the SEC at the
SEC's web site at www.sec.gov, by directing a request to Horizon's
Investor Relations department at Horizon Pharma, Inc., Attention:
Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL
60015 or to Horizon's Investor Relations department at 224-383-3000
or by email to investor-relations@horizonpharma.com. Investors and
security holders may obtain free copies of the documents filed with
the SEC on Horizon's website at www.horizonpharma.com under the
heading "Investors" and then under the heading "SEC Filings."  
Horizon and its directors and executive officers and Vidara and its
directors and executive officers may be deemed participants in the
solicitation of proxies from the stockholders of Horizon in
connection with the proposed transaction. Information regarding the
special interests of these directors and executive officers in the
proposed transaction will be included in the proxy
statement/prospectus described above. Additional information
regarding the directors and executive officers of Horizon is also
included in Horizon's Annual Report on Form 10-K for the year ended
December 31, 2013, which was filed with the SEC on March 13, 2014.
These documents are available free of charge at the SEC's web site at
www.sec.gov and from Investor Relations at Horizon as described
above.  
This communication does not constitute an offer to sell, or the
solicitation of an offer to sell, or the solicitation of an offer to
subscribe for or buy, any securities nor shall there be any sale,
issuance or transfer of securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction. 
Contact
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
investor-relations@horizonpharma.com 
 
 
Press spacebar to pause and continue. Press esc to stop.